Metagenomi Therapeutics, Inc.
MGX
DELAYED 1 MONTH

10 insider filings · Latest: Jun 9, 2026

Common Stock Transactions
Txn DateAcceptedInsiderTypeSharesAvg PriceValueShares OwnedFiling
Jun 5, 2026Jun 10 3:23 PMPamela WapnickChief Financial Officer
Sale
2,884$1.30$3.7K208,491(D)

View →

Jun 5, 2026Jun 10 3:21 PMJian IrishDirector, President and Chief Executive Officer
Sale
3,737$1.30$4.9K377,533(D)

View →

Jun 5, 2026Jun 10 3:19 PMMatthew WeinTitle: General Counsel, Compliance Officer and Corporate Secretary
Sale
558$1.30$725126,491(D)

View →

Mar 5, 2026Mar 9 9:16 PMPamela WapnickChief Financial Officer
Sale
1,581$1.60$2.5K187,375(D)

View →

Mar 5, 2026Mar 9 9:16 PMMatthew WeinTitle: General Counsel, Compliance Officer and Corporate Secretary
Sale
482$1.60$771114,549(D)

View →

Mar 5, 2026Mar 9 9:15 PMJian IrishDirector, Chief Executive Officer
Sale
1,607$1.60$2.6K333,770(D)

View →

Stock Options & Derivatives
Txn DateAcceptedInsiderTypeSharesExercise PriceShares OwnedFiling
Jun 9, 2026Jun 11 6:31 PMLaurence ReidDirector
Grant/Award
17,400$1.2317,400(D)

View →

Jun 9, 2026Jun 11 6:23 PMWillard H DereDirector
Grant/Award
21,000$1.2321,000(D)

View →

Jun 9, 2026Jun 11 5:49 PMEric BjerkholtDirector
Grant/Award
21,000$1.2321,000(D)

View →

Jun 9, 2026Jun 11 5:37 PMJuergen EckhardtDirector
Grant/Award
21,000$1.2321,000(D)

View →